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Abstract: Cancer is caused by multiple genetic alterations leading to uncontrolled cell proliferation through multiple pathways. 
  Malignant cells arise from a variety of genetic factors, such as mutations in tumor suppressor genes (TSGs) that are involved in 
  regulating the cell cycle, apoptosis, or cell differentiation, or maintenance of genomic integrity. Tumor suppressor mouse models are 
the most frequently used animal models in cancer research. The anti-tumorigenic functions of TSGs, and their role in development and 
differentiation, and inhibition of oncogenes are discussed. In this review, we summarize some of the important transgenic and knockout 
mouse models for TSGs, including Rb, p53, Ink4a/Arf, Brca1/2, and their related genes.
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Introduction
Cancer is induced by genetic and environmental factors. 
Cancer can be categorized as familial (inherited) or 
sporadic, the latter comprising the vast majority of 
cases. Germline mutations predispose an individual 
to familial cancers. When the function of remaining 
wild-type allele is lost in a somatic cell, additional 
mutation(s)  on  the  wild-type  locus  can  accumulate 
that lead to tumor formation. In sporadic cancers, all 
tumorigenic mutations are somatic and are present only 
in the patient’s neoplastic cells. In humans, mutations 
leading to gain of functions of proto-oncogenes or 
loss of functions of tumor-suppressor genes (TSGs) 
predispose to cancer. TSGs can be divided into two 
groups: “gatekeepers” and “caretakers”.1–3
Gatekeepers  regulate  the  growth  of  tumors  by 
inhibiting  their  proliferation  or  promoting  their 
apoptosis. Caretakers control cellular processes that 
repair  genetic  alterations  and  maintain  genomic 
integrity.  Mutations  of  caretakers  can  result  in  an 
increase in the overall mutation rate in a given cell, 
an  apparent  prerequisite  for  tumorigenesis.  The 
accumulation  of  mutations  in  a  dysregulated  cell 
favors  the  subsequent  clonal  selection  of  variant 
progeny with aggressive growth properties leading 
to  malignancy.  Familial  cancers  often  result  from 
the  initial  germline  mutation  of  one  allele  of  a 
TSG  followed  later  by  somatic  mutation  or  loss 
of  the  second  allele,  a  process  known  as  loss  of 
heterozygosity  (LOH).  Knudson’s  two-hit  cancer 
model4,5  is  based  on  this  repeated  observation. 
Although LOH was originally a prerequisite for the 
identification of canonical TSGs, the remaining wild-
type allele can also be transcriptionally silenced by 
hypermethylation of its CpG regions. Functional loss 
then leads to tumorigenesis.
Animal  models  have  been  instrumental  in  the 
study of genes involved in human cancer initiation 
and progression. Spontaneous as well as carcinogen-
induced malignancies have been studied in dogs, rats, 
and mice, and TSGs identified in Drosophila have 
led to the discovery of mammalian orthologues. The 
availability of null and tissue-specific mouse mutants 
for tumor-suppressor genes has greatly facilitated our 
understanding of the mechanisms leading to cancer.
The mouse remains the animal model of choice 
for several reasons. First, mice and humans have 
roughly the same number of genes, and intracellular 
  signaling pathways are highly conserved between 
the  two  species.  Second,  the  success  of  genetic 
engineering  in  mice  has  allowed  the  study  of 
gene  functions  in  vivo.  Mice  can  be  genetically 
manipulated to overexpress (by transgenesis), or not 
express (by gene targeting), a specific cancer gene. 
These animals offer unique opportunities to uncover 
cellular pathways controlled by specific TSGs and 
to dissect mechanisms underlying malignancies that 
may closely resemble those in humans. In addition, 
the interbreeding of an increasing number of mice 
with specific mutations in both TSGs and oncogenes 
allows  the  assessment  of  how  these  mutations 
cooperate to produce cancer.
Tumor models in mice include (1) mice in which 
cancer is caused by intrauterine or postnatal exposure 
to chemical mutagens, and mice in which tumors are 
produced by viral or bacterial infection, (2) xenograft 
models  that  were  generated  by  directly  implanting 
cancer  cell  lines  established  from  human  tumors 
into mice have been widely used for drug discovery, 
and  (3)  genetically  engineered  mouse  (GEM: 
constitutive or conditional transgenic, knockin, and 
knockout)  cancer  models.  The  major  limitations 
of  xenograft  models  are  the  requirement  for  an 
immunocompromized host and the inability of these 
models to fully recapitulate the complex relationship 
between  the  tumor  and  its  microenvironment 
(eg, angiogenesis). Most importantly, the ability of 
xenografts to accurately predict drug efficacy in human 
cancer patients has been disappointing. In contrast, 
GEM cancer models are becoming more and more 
sophisticated in their ability to accurately mimic the 
histology and biological behavior of human cancers.6,7 
Numerous  tissue-specific  GEM  models  have  been 
developed  that  exhibit  many  biologic  hallmarks  of 
human  cancer,  including  angiogenesis  and  stromal 
interactions,  as  well  as  similar  histopathologic  and 
genetic abnormalities. The major advantages of GEM 
models are that (i) the initiating genetic event is known, 
(ii) the mice are immunocompetent, and (iii) the tumors 
develop  spontaneously  in  their  appropriate  tissue 
compartments.  Moreover,  GEM  cancer  models  are 
particularly useful for conducting preclinical studies 
of  rare  cancers  and  for  assessing  synergy  between 
therapeutic  agents  since  they  allow  assessment  of 
therapeutic efficacy on a uniform genetic background. 
They can also potentially provide the tools needed Transgenic tumor suppressor models
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to learn more about the histological and biochemical 
effects of specific agents prior to human testing.
In this review, we have focused on recent progress 
in transgenic and knockout mouse models for TSGs 
involved in apoptosis and the cell cycle, DNA dam-
age repair, cell signaling, and differentiation, and their 
clinical implications. Special emphasis is placed on 
conditional models, knock-in models, and transgenic 
models of TSGs.
p53 models
Mouse knock-in p53 mutation models are beginning 
to establish clear p53 tumor suppressor genotype-
phenotype relationships. Previous studies identified 
a hot spot variant p53 mutation (R175H) in sporadic 
human  tumors.  R175H  functions  normally  in 
blocking cell cycle progression, but is deficient in 
promoting apoptosis, similar to the R175L variant. 
Both  p53R270H/+  and p53R172H/+  mice  are  models  for 
human  Li-Fraumeni  syndrome,  and  importantly 
develop  epithelial  tumors  that  are  not  found  in 
p53-/- mice, including carcinomas in the lung, small 
intestine,  colon,  breast,  skin,  liver,  and  pancreas, 
and more frequent endothelial tumors. Thus, point 
mutant  p53  alleles  expressed  under  physiological 
control have enhanced oncogenic potential beyond 
the simple loss of p53 function. p53 gain-  of-function 
knock-in  models  develop  carcinomas  rather  than 
sarcomas  within  one  year,  and  are  thus  more 
faithfully reproduce human carcinomas than classical 
p53 knock-out models. These novel p53  knock-in 
mice will be useful in drug screens for carcinomas. 
Mutant mice that constitutively express activated p53 
showed enhanced resistance to spontaneous tumors 
compared with wild-type littermates and displayed 
an early onset of phenotypes associated with ageing.
p53, located on the human chromosome 17p13.1, 
is  one  of  the  most  extensively  studied  TSGs.6–10 
  Li-Fraumeni syndrome is caused by inherited TP53 
mutations  and  associated  with  high  susceptibility 
to breast and lung carcinomas, soft tissue sarcomas 
(STSs) brain tumors, osteosarcoma, and leukemias. 
The p53 transcript encodes a 393-aa nuclear phos-
phoprotein of 53 kDa. The p53 protein exists as a 
tetramer  exhibiting  its  tumor-suppressive  effect  by 
binding to DNA at specific sites. p53 activity is mod-
ulated by protein stability, regulated largely through 
interactions with the E3 ligase Mdm2.
Binding of Mdm2 to p53 leads to p53 degradation 
and loss of activity, a process that can be inhibited by 
the gatekeeper protein Arf (Fig. 1). Post-translational 
modifications mediate p53 activity by phosphoryla-
tion, acetylation, sumoylation, or glycosylation. p53 
activation is triggered by hyperproliferative mitogenic 
signals mediated through deregulated Myc, Ras, or 
E2F-1, which in turn mediates the induction of Arf 
expression  which  promotes  p53  stabilization  and 
activation (Fig. 1).9 p53 activity is also induced in 
response to DNA damage and involves the regulatory 
kinases ATM, CHK2, and ATR (Fig. 1).
Activated  p53  acts  as  a  regulator  of  cellular 
processes such as cell cycle, apoptosis, autophagy, 
and  differentiation.  Numerous  p53  transcriptional 
targets  have  been  identified,  including  p21Cip1/Waf1, 
Mdm2, Bax, Puma (Bbc), Noxa, Pig8, Gadd45, Pidd, 
p53R2, DR5, cyclin G, Pten, and CD9.8 Conversely, 
p53  transcriptionally  represses  bcl-2,  PCNA,  and 
Arf.  p53  activation  controls  the  G1  checkpoint  of 
the cell cycle by inducing transcription of the cyclin/
Cdk inhibitor p21Cip1/Waf1. Cells with damaged DNA 
are prevented from entering S phase and replicating 
the  defective  chromosomes.  p53  controls  the  G2 
checkpoint  by  regulating  expression  of  p21Cip1/Waf1 
and Snk/Plk2.11,12 The arrest of the cell cycle at these 
checkpoints  allows  repair  of  the  damaged  DNA. 
Transcriptional  activation  of  pro-apoptotic  genes 
including Bax, Puma, Noxa, PIDD, DR5, and CD95 
are dependent on p53.
p53 knockout models
Four strains of mice bearing null mutations of p53 
have been created.13–16 Although initial studies of p53-/- 
mice concluded that p53 had no role in development, 
subsequent work has revealed that a subset of p53-
deficient embryos dies in utero. This embryonic death 
is associated with exencephaly marked by defects in 
neural tube closure and overgrowth of neural tissue 
in the midbrain region.17,18 The finding that Mdm2-/-
mutants, which die before E6.5, can be fully rescued 
in a p53-null background suggests that p53 activity 
must be tightly regulated by Mdm2 for successful 
development.19,20
As expected, p53+/- mice are predisposed to tum-
origenesis. These animals remain cancer-free for the 
first 9 months, but half develop osteosarcomas, soft 
tissue sarcomas, and lymphomas by 18 months of age. Taneja et al
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Most tumors from p53+/- mice show LOH of the wild-
type p53 allele. In p53-/- mice, the onset of tumor 
development is earlier than in heterozygotes; more 
than  75%  of  p53-/-  mice  develop  tumors  before 
6 months of age. While thymic T cell lymphomas are 
the major tumor type, p53-/- mice also develop B cell 
lymphomas, sarcomas, and testicular teratomas.15 The 
enhanced susceptibility to cancer of p53-/- mice results 
in their death before 10 months of age. p53-deficient 
mice are also extremely susceptible to tumorigenesis 
induced by ionizing radiation (IR) or carcinogens.21,22
Patients with Li-Fraumeni syndrome have germ-
line  TP53  mutations,  and  therefore  50%  of  them 
develop malignancies by the age of 30,23 comparable 
to the tumor incidence in middle-aged (18 months) 
p53+/-  mice.  The  spectrum  of  tumors  that  arise  in 
Li-Fraumeni patients is generally similar to that in 
p53+/- mice. However, human patients also develop 
breast  cancers  and  brain  tumors,  which  are  rarely 
observed  in  p53+/-  mice.  These  differences  were 
puzzling  until  p53-/-  mice  were  crossed  into  the 
BALB/c background. Spontaneous mammary tumors 
developed  in  half  of  the  heterozygous  females  of 
this strain,24 and the tumors showed the loss of the 
remaining wild-type p53 allele. Furthermore, when 
mammary  glands  from  p53-/-  BALB/c  mice  were 
transplanted into wild-type BALB/c hosts, 75% of 
the transplanted mice developed mammary tumors. 
Thus,  differences  in  genetic  background  can  have 
profound effects on the types of tumors associated 
with p53 mutation in mice.
In addition to their use as an animal model for p53-
associated cancers, p53-/- mice have also been helpful 
in determining p53 functions in vivo. p53 is required 
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Figure 1. Molecules that are characterized in this review. Mitogenic signals acting through Ras stimulate the formation of cyclin D/Cdk complexes 
that phosphorylate RB in mid-late G1 phase. Accentuated by cyclin e/Cdk2 (not shown), RB phosphorylation interrupts its interactions with both histone 
deacetylase and e2Fs, enabling e2Fs to promote S phase entry. Myc plays a similar role in the sense that it is capable of accelerating S phase entry.181–183 
All D-type cyclins are mitogen-responsive, but only cyclin D1 is Ras-responsive. One of the oncogenic effects of adenovirus e1A and papilloma virus e7 
is to interfere with RB function. By inhibiting cyclin D-dependent kinase activity, p16INK4a acts as a potent tumor suppressor. p16Ink4a, p19Arf, and tumor sup-
pressor Dmp1 are induced in response to oncogenic Ras-Raf-Mek-erk signaling. This Arf induction (and also p16Ink4a and Dmp1) quenches inappropriate 
mitogenic signaling by diverting incipient cancer cells to undergo p53-dependent and independent growth arrest or cell death. Arf is also induced by acti-
vated other potentially oncogenic signals stemming from overexpression of oncogenes such as c-Myc, e2F1. Arf expression is repressed by a number of 
nuclear proteins, such as Bmi1, Twist, Tbx2/3, and Pokemon. Dmp1 (cyclin D binding myb-like protein 1; Dmtf1)116,117,184–186 is unique in that it directly binds 
and activates the Arf promoter and induces cell cycle arrest in an Arf-dependent fashion. The Dmp1 promoter is also activated by HeR2 overexpression.187 
Both Dmp1-null and heterozygous mice show hypersensitivity to develop tumors in response to carcinogen DMBA and γ-irradiation,117 suggesting haploid 
insufficiency. D-type cyclins inhibit Dmp1’s transcriptional activity in a Cdk-independent fashion when e2Fs do not bind to the same promoter; however, 
D-cyclins cooperate with Dmp1 to activate the Arf promoter. BRCA1/2 proteins are directly or indirectly phosphorylated by ATM/ATR kinases in response 
to DNA damage, which will interact with p53 to stop cell cycle by activating the p21Cip1/WAF1 promoter. DNA damage (as indicated by the horizontal lines) 
has been shown to access the Mdm2-p53 machinery independently of Arf. However, Arf-loss enables Mdm2 to work more efficiently in antagonizing p53 
function in response to DNA damage.Transgenic tumor suppressor models
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for  thymocyte  apoptosis  induced  by  double-strand 
DNA breaks (DSBs) in response to stimuli such as 
ionizing  radiation  and  adriamycin,  but  dispensable 
both for the apoptosis that mediates negative selection 
of  immature  thymocytes  and  thymocyte  apoptosis 
induced in response to ultraviolet irradiation, dexam-
ethasone, or anti-CD95.25,26 With respect to cell cycle 
control, cells from p53-/- mice show enhanced prolif-
eration in culture compared to controls.27 With respect 
to  maintenance  of  genomic  integrity,  p53-/-  MEFs 
cultured in vitro show a high degree of aneuploidy, a 
hallmark for genomic instability.27 p53 has also been 
implicated as a component of a spindle checkpoint 
that ensures the maintenance of diploidy. p53-/- fibro-
blasts exposed to spindle inhibitors performed mul-
tiple rounds of DNA synthesis without completing 
chromosome segregation, resulting in tetraploid and 
octaploid cells.28 Increased genomic instability is also 
seen in mice deficient for Gadd45α, a transcriptional 
target of p53.29
Tumor suppressors and oncogenes are presumed to 
cooperate in the induction of tumorigenesis. A p53-/- 
background dramatically increases tumor frequency 
and reduces the latency in c-Myc transgenic mice.30 
A  cooperative  effect  on  transformation  between 
p53 and Rb mutations has also been reported. Mice 
carrying mutations of both p53 and Rb have reduced 
viability and exhibit abnormalities not observed with 
either  single  mutant,  including  pinealoblastomas, 
islet cell tumors, bronchial epithelial hyperplasia, and 
retinal dysplasia.31
The generation of p53 conditional knockout mice 
with floxed alleles has shed further light on p53 tumor-
suppressor function in vivo.32 Medulloblastomas are 
among the most common malignancies in childhood, 
and they are associated with substantial mortality and 
morbidity. Marino et al generated a mouse model for 
medulloblastoma by Cre–LoxP-mediated inactivation 
of Rb and p53 TSGs in the cerebellar external granular 
layer (EGL) cells. GFAP–Cre-mediated recombination 
was found both in astrocytes and in immature precursor 
cells of the EGL in the developing cerebellum. GFAP-
Cre; RbLoxP/LoxP; p53-/- or LoxP/LoxP mice developed 
highly aggressive embryonal tumors of the cerebellum 
with typical features of medulloblastoma. These tumors 
were identified as early as 7 weeks of age on the outer 
surface of the molecular layer, corresponding to the 
location of the EGL cells during development.32
p53 knock-in mice
Heterozygous  mice  expressing  mutant  mouse  p53 
with  an  R172H  substitution  (corresponding  to  the 
R175H mutation “hot-spot” in human tumors) develop 
osteosarcomas,  carcinomas,  and  lymphomas  with 
high metastatic potential.34 LOH studies of p53R172H∆g 
tumors indicated loss of the wild-type p53 allele in only 
1 of 11 tumors. These data indicated clear differences 
between a p53 missense mutation and a null allele in 
tumorigenesis in vivo, and suggest that the p53R172H∆g 
mutant  represents  a  gain-of-function  allele.34  Mice 
with a p53 allele altered at Leu25 and Trp26, residues 
essential for transcriptional transactivation and Mdm2 
binding,  synthesized  a  p53  protein  that  was  stable 
but did not accumulate after DNA damage.35,36 The 
mutant p53L25W26 was abundantly expressed, and the 
level was not affected by DNA damage, but bound 
to  DNA  constitutively;  however,  mutant  p53L25W26 
showed defects in cell-cycle regulation and apoptosis. 
Both  p53L25W26  mutant  and  p53-null  mouse  MEFs 
were  readily  transformed  by  oncogenes,  and  the 
corresponding  mice  were  prone  to  tumors.  Thus, 
the  determining  pathway  for  p53  tumor-suppressor 
function in mice requires the transactivation domain.
To  examine  the  mechanistic  nature  of  p53 
missense  mutations  found  in  individuals  with 
Li-Fraumeni syndrome, Lang et al37 generated mice 
harboring a G-to-A substitution at nucleotide 515 of 
p53 (p53+/515A) corresponding to the p53R175H hot spot 
mutation in human cancers. Although p53+/515A mice 
display a similar tumor spectrum and survival curve as 
p53+/- mice, tumors from p53+/515A mice metastasized 
with high frequency. Correspondingly, MEFs from 
the p53515A/515A mutant mice displayed enhanced cell 
proliferation,  DNA  synthesis,  and  transformation. 
They also reported that disruption of p63 and p73 
in  p53-/-  cells  increased  transformation  capacity 
and  re-initiated  DNA  synthesis  to  levels  observed 
in p53515A/515A cells. Additionally, p63 and p73 were 
functionally inactivated in p53515A cells. Their results 
provided in vivo validation for the gain-of-function 
properties  of  certain  p53  missense  mutations  and 
suggested a mechanistic basis for these phenotypes.
Similar phenotypes were found in  p53 knock-in mice 
created by Olive et al.38 To ascertain the physiological 
effects of p53 point mutation, the structural mutant 
p53R172H and the contact mutant p53R270H (corresponding 
to codons 175 and 273 in humans) were engineered into Taneja et al
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the endogenous p53 locus in mice. Both p53R270H/+ and 
p53R172H/+ mice are models of Li-Fraumeni syndrome; 
they developed allele-specific tumor spectra distinct 
from p53+/- mice. In addition, p53R270H/- and p53R172H/- 
mice developed novel tumors that were not found in 
p53-/- mice, including carcinomas in the lung, small 
intestine, colon, breast, skin, liver, and pancreas, and 
more frequent endothelial tumors.38 Dominant effects 
that varied by allele and function were observed in 
primary cells derived from p53R270H/+ and p53R172H/+ 
mice. These results demonstrate that point mutant p53 
alleles  expressed  under  physiological  control  have 
enhanced oncogenic potential beyond the simple loss 
of p53 function.
Transgenic overexpression models for p53
Lavigueur  et  al39  established  p53-transgenic  mice 
driven by the endogenous promoter using murine p53 
genomic fragments isolated from a Friend cell line 
CB7 or BALB/c mouse liver DNA. Mutations in Arg 
to Pro in 193 or Ala to Val in 135 in p53 gene resulted 
in  multi-organ  neoplasias  including  lymphomas, 
osteosarcomas,  and  lung  adenocarcinomas.  Godley 
et al33 created transgenic mice expressing wild-type 
murine p53 under the control of the mouse mammary 
tumor virus terminal repeat (MMTV-LTR). The p53 
transgene was unexpectedly expressed in the kidney, 
which  underwent  progressive  renal  failure  due  to 
abnormal  kidney  development.  Similar  phenotypes 
were observed in two transgenic lines that express 
wild-type p53 within the ureteric bud, but not in trans-
genic animals expressing a dominant-negative p53 
mutant allele. Defective differentiation of the ureteric 
bud, as evidenced by altered marker expression dur-
ing development, was accompanied by expression of 
the p53 transgene. At E17.5–18.5, metanephric mes-
enchymal  cells  underwent  high  rates  of  apoptosis, 
and fewer cells than normal were converted to tubu-
lar epithelium.33 Proteinuria was observed as early 
as 2 weeks of age, with azotemia began at 6 weeks. 
As a result, kidneys in these animals grew to only 
half of their expected size and contained about half 
of the normal number of nephrons, with compensa-
tory  hypertrophy  of  the  glomeruli.  Most  affected 
glomeruli showed global glomerulosclerosis. In this 
setting,  abnormally  high  levels  of  wild-type  p53 
altered cellular differentiation in embryonic ureteric 
buds, and caused secondary effects (apoptosis and 
inefficient conversion to epithelium) in the adjacent 
undifferentiated mesenchyme.33
p53 activation vs. overexpression  
models and ageing
The role of p53 on ageing has also been studied. Tyner 
et al40 generated mice with a deletion mutation in the 
first six exons of the p53 gene that express a truncated 
RNA  capable  of  encoding  a  carboxyl-terminal 
p53  fragment.  This  mutation  confers  phenotypes 
consistent with activated, rather than inactivated, p53. 
Mutant (p53+/m) mice showed enhanced resistance to 
spontaneous tumors compared with wild-type (p53+/+) 
littermates.  As  p53+/m  mice  aged,  they  displayed 
an  early  onset  of  phenotypes  associated  with 
ageing,  including  reduced  longevity,  osteoporosis, 
generalized  organ  atrophy  and  a  diminished  stress 
tolerance.40  By  contrast,  the  phenotypes  of  p53-/m 
mice  were  in  distinguishable  from  those  of  p53-/- 
mice, suggesting that a normal p53 allele is required 
for  the  mutant  p53  gene  to  have  an  effect.  The 
tumor resistance of p53+/m mice was considered to 
be  intrinsic  to  the  individual  cells  of  the  animals, 
since fibroblasts from p53+/m were more resistant to 
transformation by activated Ras plus Myc oncogenes 
(although  this  does  not  rule  out  the  possibility  of 
systemic hormonal, immunological or growth factor 
changes). The association of early ageing and tumor 
resistance in the p53+/m mice is consistent with the idea 
that senescence is a mechanism of tumor suppression. 
They suggested that ageing-related reduction in stem 
cell proliferation might have a more important role 
in longevity than previously recognized.40,41
Garcia-Cao  et  al42  established  and  characterized 
mice carrying supernumerary copies of the wild-type 
p53 gene as large genomic transgenes. They showed 
that the p53 transgenic allele (p53-tg), when present in 
a p53-null genetic background, behaves as a functional 
replica of the endogenous gene. “Super p53” mice that 
carry p53-tg alleles in addition to the two endogenous 
alleles  exhibited  an  enhanced  response  to  DNA 
damage and were significantly protected from cancer 
when compared with normal mice. It is conceivable 
that constitutive or highly frequent activation of p53, 
such as under chronic exposure to stress, could result in 
accelerated aging as demonstrated by Tyner et al.40 In 
contrast, “super p53” mice have a normal aging process 
despite having clearly increased p53 functionality.42Transgenic tumor suppressor models
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A critical characteristic of the “super p53” mice 
is that basal levels of p53 activity are not affected. 
Attempting to further increase the gene dosage of p53 
may eventually reveal a threshold at which deleterious 
effects will be noticeable, probably as defective tissue 
regeneration, growth atrophies, and premature aging. 
This  suggests  that  increases  in  normally  regulated 
p53,  as  in  the  “super  p53”  mice,  could  confer 
cancer protection without affecting ageing, whereas 
constitutive  levels  of  active  p53  provides  cancer 
protection, but promote aging. Thus, cancer resistance 
could be enhanced by a simple genetic modification 
of p53 in the absence of undesirable effects.
p73 and p63 models
There is no convincing clinical evidence that p73 or 
p63 plays a significant role in human tumorigenesis. 
The  combined  absence  of  p63  and  p73  severely 
impaired the induction of p53-dependent apoptosis 
in response to DNA damage in oncogene-expressing 
cells and in the developing central nervous system 
in mice, which was explained by the inability of p53 
to bind the promoters of apoptosis-associated target 
genes and to upregulate their transcription. Thus, there 
are two classes of p53-family target genes. One class 
includes genes such as Mdm2 and p21Cip1/Waf1, which 
p53 regulates in the presence or absence of p63 /p73, 
and the other group includes genes Perp, Bax, and 
Noxa that require p63/p73 for p53 to be recruited and 
function properly. Thus, p63 and p73 are important 
components of the cellular response to DNA damage, 
and  may  portend  a  greater  role  for  these  proteins 
in  tumor  suppression  and  chemosensitivity.  The 
validation of p73 and p63 as novel tumor suppressors 
may offer novel therapeutic approaches to enhance the 
chemosensitivity of tumor cells harboring mutated or 
inactivated p53.
p73 and p63 are members of the p53 family of 
proteins and thus attractive candidates for TSGs.43,44 
Both p73 and p63 share significant amino acid identity 
with p53 in the transactivation domain, the DNA-
binding domain, and the oligomerization domain. Like 
p53, p73 and p63 can recognize canonical p53 DNA-
binding sites and, when overproduced, can activate 
p53-responsive target genes and induce apoptosis.43 
p73 is localized to chromosome 1p36.3, a region of 
frequent aberrations in human cancers, such as thyroid, 
colorectal, and breast cancers, pheochromocytomas, 
and brain tumors.45 However, there is no convincing 
clinical evidence that p73 and p63 play a significant 
role in human tumorigenesis. E2F-1 directly activates 
transcription  of  p73  leading  to  activation  of  p53-
responsive target genes and apoptosis.46–49 Moreover, 
synergistic  cooperation  between  YY1  and  E2F-1 
through  physical  interaction  was  reported  in  the 
regulation of the p73 promoter.50
Disruption of p73 function inhibits E2F-1-induced 
apoptosis  in  p53-deficient  cells,  suggesting  a  role 
for  p73  in  p53-independent  apoptosis.  Similarly, 
T cell receptor activation-induced cell death, which 
is  p53-independent,  is  inhibited  in  the  absence  of 
p73.47 Interestingly, a truncated isoform of p73 that 
is expressed in developing neurons appears to have 
an anti-apoptotic function.51 However, other evidence 
weighs  against  a  tumor-suppressive  role  for  p73. 
Knockout  mice  null  for  p73  lacked  an  increased 
incidence of tumors up to 15 months of age.52 Several 
p73 isoforms and two different p73 promoters have 
been described. Mice deficient for specific isoforms 
of p73 remain to be reported. Mice deficient for p63 
show defects in limb and epidermal morphogenesis 
and die within hours of birth,53,54 but did not show 
increased  incidence  of  tumor  formation.  The 
combined absence of p63 and p73 severely impaired 
the induction of p53-dependent apoptosis in response 
to DNA damage in E1A-  expressing cells and in the 
developing  central  nervous  system  in  mice.55  This 
was  explained  by  the  inability  of  p53  to  bind  the 
promoters of apoptosis-associated target genes and 
to upregulate their transcription in p63-/-; p73-/-; E1A 
cells and the developing central nervous system.
These data support the notion that there might be 
two  classes  of  p53-family  target  genes.  One  class 
includes genes such as Mdm2 and p21Cip1/Waf1, which 
p53 regulates in the presence or absence of p63 and 
p73. The other group includes genes such as Perp, 
Bax, and Noxa that require p63 or p73 for p53 to be 
recruited  and  function  properly.  These  data  show 
that p63 and p73 are important components of the 
response to DNA damage, and may portend a greater 
role  for  these  proteins  in  tumor  suppression  and 
chemosensitivity.  The  same  group  later  conducted 
a  detailed  study  to  determine  whether  p63  or  p73 
are involved in tumor suppression using aging mice 
heterozygous for mutations in all p53 family genes.56 
They used p73+/- mice for tumor observation, since Taneja et al
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only  25%  of  p73-/-  mice  survived  to  adulthood 
in  their  colony.  Spontaneous  tumors  developed 
in  p63+/-;  p73+/-  mice,  including  mammary  and 
lung  adenocarcinomas,  thymic  and  squamous  cell 
carcinoma, and myeloid leukemia. Loss of p63 and 
p73 can also cooperate with loss of p53 in tumor 
development.  Mice  heterozygous  for  mutations  in 
both p53 and p63 or p53 and p73 displayed higher 
tumor burden and metastasis compared to p53+/- mice. 
These findings provide evidence for a broader role for 
the p53 family in tumor suppression than has been 
previously reported.56
Retinoblastoma models
The retinoblastoma gene family is composed of three 
members:  the  product  of  the  retinoblastoma  gene 
(pRb), and two related proteins, pRb2/p130 and pRb3/
p107, which have been shown to be structurally and 
functionally similar to pRb. The three retinoblastoma 
family members show growth suppressive properties, 
although the growth arrest mediated by each of the 
three pocket regions of the proteins is not identical. 
Although the three pRB members complement each 
other,  they  are  not  functionally  redundant. Among 
these proteins, pRb and p130 are tumor   suppressor 
proteins,  and  thus  are  candidate  targets  for  gene 
  therapy. Mutations commonly found in human small 
cell lung carcinomas (SCLC) are inactivation of RB 
and TP53. Recent study established a mouse model 
for neuroendocrine lung tumors by conditional inac-
tivation of both Rb and p53 in mouse lung epithelial 
cells. These murine small cell lung carcinoma models 
may be beneficial for novel drug screening of SCLC.
Retinoblastoma (RB) is an eye tumor that occurs 
in children. The RB gene is located on chromosome 
13q14.2, and mutations of RB have been found in both 
inherited and sporadic cases.57 RB mutations can also 
predispose individuals to osteosarcomas, and prostate 
and breast cancers. In adults, human papilloma virus 
(HPV) is thought to initiate cervical carcinoma and 
squamous cell carcinoma of the head and neck, at 
least in part by inactivating RB through expression 
of  the  E7  oncoprotein  (Fig.  1). Viral  oncoproteins 
such  as  adenovirus  E1A  and  SV40  large  tumor 
antigen can bind to the RB protein and inactivate its 
function (Fig. 1). In liver cancer, hepatitis C virus 
induces E6 associated protein (AP) degradation of 
RB.58 Moreover, RB is inactivated in more than 90% 
of human small-cell lung carcinomas (SCLC),59 and 
mouse genetic studies have confirmed that Rb plays 
crucial roles in preventing the initiation of SCLC.60
The RB gene encodes a 928-amino acid (aa) nuclear 
protein of 105 kDa.61–64 Phosphorylation of the RB 
protein, which is critical for regulation of its function, 
is mediated by cyclin/cyclin dependent kinase (CDK) 
complexes in vivo. Phosphorylation of RB is thus 
cell cycle-dependent, with the hypophosphorylated, 
active  form  being  present  in  G0/G1,  and  the 
hyperphosphorylated,  inactive  form  dominant  in 
late  G1  of  the  cell  cycle  (Fig.  1).62–64  Inactivation 
of RB by germline mutation of one allele and LOH 
of the second allele is often found in RB-associated 
cancers. However, functional inactivation of the RB 
protein in the absence of RB mutation can also lead 
to tumorigenesis. For instance, amplification of the 
11q13  region  results  in  cyclin  D1  overexpression, 
which, in turn, leads to activation of cyclin D-CDK4/6 
activity and hyperphosphorylation and inactivation of 
RB.65 Functional inactivation of RB can also occur 
from  deficient  p16INK4a  function  caused  by  gene 
deletion, promoter methylation, or point mutation.66
The  function  of  RB  is  to  repress  the  transcrip-
tion of genes required for DNA replication and cell 
division. At least two different mechanisms may be 
involved.  Binding  sites  for  the  transcription  factor 
E2F  are  present  in  the  promoters  of  many  genes 
whose expression is essential and limiting for entry 
into  S  phase.67,68  RB  binds  members  of  the  E2F 
family  (E2F1–4),  forming  a  complex  that  inhibits 
transcriptional activation. The RB-E2F complex can 
also  actively  repress  transcription  of  genes  further 
downstream.69  In  addition  to  cell  cycle  regulation, 
RB  plays  a  role  in  apoptosis.  Increased  apoptosis 
is  observed  in  gene-targeted  Rb-deficient  (Rb-/-) 
embryos, and MEFs from Rb-/- mice show activation 
of E2F-responsive genes and apoptosis.70,71 Published 
studies have indicated specific roles of E2F1 in apop-
tosis among the E2F proteins.72 E2F1 activates p73 
transcription,46,47 which, in turn, stimulates the tran-
scription of p53-responsive target genes and induces 
apoptosis.49 Published studies found that activation of 
E2F2 or E2F3a could also lead to cell death, albeit 
not to the same degree as E2F1 expression.73,74
Since  both  E2F2  and  E2F3a  can  activate  pro-
  apoptotic gene transcription, at least when overex-
pressed, the unique role of E2F1 to induce apoptosis Transgenic tumor suppressor models
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in certain conditions may depend on other specific 
properties,  such  as  E2F1-specific  interacting  pro-
teins. Intriguingly, E2F3a did not cause apoptosis in 
the absence of E2f1.75 Thus, the accumulation of cru-
cial levels of E2F1 activity, and not total E2F activ-
ity, appears essential for the induction of apoptosis in 
response to a deregulated RB pathway.
Knockout models for Rb, p107, and p130
Gene-targeted  Rb-/-  embryos  die  in  utero  between 
E13.5-E15.5.76–78 Increased apoptosis in the nervous 
system is seen as early as E11.5 and is particularly 
evident in the hindbrain, spinal cord, and trigeminal 
and dorsal root ganglia. Ectopic mitoses were also 
observed,  especially  in  the  hindbrain.  In  addition 
to  defective  neurogenesis,  Rb-/-  embryos  exhibit 
defective hematopoiesis, manifested as an increased 
number  of  immature  nucleated  erythrocytes. 
Interestingly, apoptosis in lens fiber cells deficient for 
Rb is dependent on p53, since Rb-/-; p53-/- embryos 
show a complete suppression of apoptosis.79 Analyses 
of viable chimeric mice derived from Rb-/- embryonic 
stem  cells  revealed  that  the  Rb-deficient  cells 
contribute widely to adult tissues.80,81 The chimeric 
erythroid and central nervous system compartments 
appeared  normal,  but  the  developing  retina  was 
defective and displayed ectopic mitoses.
The  effects  of  E2f-1  mutation  on  Rb  mutant 
phenotypes in mice have been examined. Rb-/-; E2f1-/- 
embryos die in utero at approximately E17 with anemia 
and defective skeletal muscle and lung development.82 
Significant  tissue-specific  suppression  of  apoptosis, 
S phase entry, and p53 activation was observed in Rb; 
E2f1 knockout cells. The fact that mutation of E2f1 did 
not fully rescue the Rb developmental defects indicates 
that these abnormalities are not entirely E2f1-dependent. 
Genomic deletion of either E2f1 or E2f3 suppresses both 
increased proliferation and apoptosis in the lens and 
nervous system of Rb-/- embryos, suggesting that both 
E2f1 and E2f3 are required for induction of apoptosis 
due to loss of Rb.82,83 Intriguingly, a portion of Rb-/-; 
E2f3+/-  embryos  exhibited  suppression  of  increased 
apoptosis, but not ectopic proliferation in the peripheral 
nervous system.83 This suggests that E2f3 has a primary 
role in induction of apoptosis due to Rb-loss, rather 
than  simply  contributing  to  abnormal  proliferation 
and resultant apoptosis of Rb-null cells. More recently, 
de Bruin et al reported that many defects in the Rb-/- 
embryos are indirectly due to an essential role of Rb in 
placental development; however, the lens defects and 
peripheral nervous system abnormalities appear to be 
cell-autonomous, suggesting that E2f may indeed play 
a direct role in regulation of proliferation and apoptosis 
in these tissues.84 Id2 is a dominant-negative antagonist 
of  basic  helix-loop-helix  transcription  factors  and 
proteins  of  the  Rb  family.  Id2;Rb  double  knockout 
(DKO) embryos survive to term with minimal or no 
defects in neurogenesis and hematopoiesis, but they 
die at birth from severe reduction of muscle tissue.85
Unlike humans, the Rb chimeras develop pituitary 
gland tumors rather than retinoblastomas.77 A similar 
phenotype was observed in Rb+/- mice that, at age 
8–10 months, developed tumors in the brain and pituitary 
gland. These tumors exhibited LOH of the remaining 
wild-type Rb allele, demonstrating that Rb is a TSG 
in mice as well as in humans. Although Rb+/- mice 
are tumor-prone, they do not accurately recapitulate 
the tumor spectrum observed in humans with RB, 
since other members of the Rb family can compensate 
for Rb-loss in murine eyes. Chimeras possessing cells 
deficient for both Rb and its family member p107 
developed retinoblastomas during the early postnatal 
months.86  Only  Rb-/-;  p107-/-  chimeras,  but  not 
Rb+/-; p107-/- chimeras, developed retinoblastomas, 
suggesting that the low number of target cells in the 
murine retina precludes the acquisition of the required 
number of mutations to inactivate the remaining Rb 
allele. Mice homozygous for loss of p107 or p130 
are viable, fertile, and healthy.62,78 However, p107-/-; 
p130-/- mice experience neonatal lethality,62 and most 
Rb+/-;  p107-/-  mice  are  growth-retarded.  Increased 
mortality of these mice is observed within the first 
three weeks of birth.78 Although Rb+/-; p107-/- pups 
that survive to adulthood do not show an increased 
cancer predisposition compared to Rb+/- mice, they 
develop  multiple  dysplastic  lesions  of  the  retina.78 
Thus,  unlike  Rb,  p107  and  p130  are  not  required 
for  embryonic  development,  and  p107+/-,  p130+/-, 
p107-/-,  and  p130-/-  mice  do  not  show  increased 
incidence of tumor development.62 Embryonic stem 
cells  with  a  simultaneous  deficiency  of  Rb,  p107, 
and  p130  (triple  knockout,  TKO)  have  normal 
growth  characteristics,  but  impaired  differentiation 
capacity.87,88  Rb,  p107;   p130  TKO  MEFs  have  a 
shorter  cell  cycle  compared  to  controls  and  can 
spontaneously immortalize. TKO mouse embryonic Taneja et al
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fibroblasts are also resistant to G1 arrest following 
DNA damage, contact inhibition or serum starvation.
Conditional  mutant  mice  for  Rb32  have  been 
  generated  using  the  Cre-LoxP  system  and  should 
prove useful in defining stage- and tissue-specific roles 
of Rb. Mutations commonly found during the patho-
genesis of human lung cancer are inactivation of RB 
and TP53; and have been identified in up to 90% of 
human SCLCs. Meuwissen et al53 established a mouse 
model for neuroendocrine lung tumors by conditional 
inactivation of Rb and p53 in mouse lung epithelial 
cells. Mice carrying conditional alleles for both Rb 
and p53 frequently developed aggressive lung tumors 
with  striking  morphologic  and  immunophenotypic 
similarities to human SCLC. Most of these tumors, 
which they designated MSCLC (murine small cell 
lung carcinoma), diffusely spread through the lung 
and gave rise to extrapulmonary metastases. In this 
model, inactivation of both Rb and p53 was a prereq-
uisite for the pathogenesis of SCLC.
Mutation of RB and TP53 tumor suppressors is 
associated with the development of human osteosar-
comas. To establish a mouse model of osteosarcomas 
in mice, Berman et al89 used conditional mouse strains 
to inactivate Rb and/or p53 specifically in osteoblast 
precursors. The resulting Rb; p53 DKO animals were 
viable,  but  developed  early  onset  osteosarcomas 
with complete penetrance. These tumors displayed 
many features of human osteosarcomas, including 
being highly metastatic. Cell lines from the DKO 
osteosarcomas  and  were  highly  proliferative  and 
retained  their  tumorigenic  potential,  multipotency, 
and expression of Sca-1, a marker that is typically 
associated with stem cells/uncommitted progenitors. 
  Tumorigenicity of the osteosarcoma cell lines corre-
lated with the presence of the Sca-1 marker. Finally, 
loss of Rb and p53 in Sca-1-positive mesenchymal 
stem/progenitor cells was sufficient to yield trans-
formed cells that can initiate osteosarcoma forma-
tion in vivo.
Choi et al90 later inactivated the Rb and p53 genes 
by Cre-loxP-mediated recombination in mice. More 
than 90% of mice developed spindle cell/pleomorphic 
sarcomas  after  a  single  subcutaneous  injection  of 
adenovirus  carrying  Cre-recombinase.  Similar  to 
human STSs, these sarcomas overexpressed Cxcr4, 
which contributes to their invasive properties. Sarcomas 
originated not from bone marrow-derived cells, but 
from local resident cells. Indeed, dermal mesenchy-
mal stem cells isolated by plastic adherence and low 
levels of Sca-1 expression (Sca-1low, CD31negCD45neg) 
have shown enhanced potential for malignant trans-
formation after the conditional inactivation of both 
p53 and Rb. Sarcomas formed after transplantation 
of these cells had features typical for undifferentiated 
high-grade  pleomorphic  sarcomas.  Together,  these 
results indicated that local Sca-1low dermal mesenchy-
mal stem/progenitor cells are preferential targets for 
malignant  transformation  associated  with  deficien-
cies in both p53 and Rb.
Transgenic model for Rb
Transgenic mice containing 1–7 copies of a human 
RB cDNA transgene under the transcriptional control 
of the human RB promoter have been generated.91 
Most  of  these  transgenic  mice  were  smaller  than 
  non-transgenic littermates, which were found as early 
as embryonic day 15. The degree of dwarfism corre-
lated roughly with the copy number of the transgene 
and the corresponding level of RB protein. Transfer-
ring the transgene to Rb-deficient mice, which are 
nonviable,  resulted  in  the  development  of  normal, 
healthy  mice,  indicating  that  the  human  RB  gene 
can functionally complement the mouse homolog,91 
and suggesting that regulation of Rb expression is 
required for normal development.
Nikitin  et  al92  generated  tetracycline-regulated 
Rb transgenic mice to explore the potential mecha-
nism of Rb effects on somatic growth, and compared 
their  phenotypes  to  those  of  previously  estab-
lished Rb mouse models. By gestational day 12.5, 
embryos lacking Rb and those expressing twice the 
normal level of Rb were 15% larger and 10%–30% 
smaller, respectively, compared with their wild-type 
littermates. The small mouse (dwarf) phenotype of 
Rb transgenic mice was associated with increased 
plasma levels of insulin-like growth factor-I (IGF-I), 
but not with growth hormone and glucose concentra-
tions.92 Notably, down-regulation of the Rb transgene 
expression reduced IGF-I plasma concentrations to 
normal levels and increased somatic growth pre- and 
postnatally. Consistent with the in vivo results, cells 
overexpressing Rb required higher thresholds of IGF-I 
to stimulate proliferation. Thus, the IGF-I pathway 
is a critical target for Rb to regulate mouse somatic 
growth and maintenance during ontogenesis.92Transgenic tumor suppressor models
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Ink4a/Arf models
The frequent mutation or deletion of INK4a/ARF in 
human tumors as well as the occurrence of tumors in 
the murine knockout models have identified both p16 
and Arf as bona fide tumor suppressors. INK4-ARF 
deletions  frequently  occur  in  clinically  aggressive 
acute  lymphoblastic  leukemias  (Ph(+)  ALLs),  but 
are not in more indolent Ph(+) chronic CML or in 
CML  myeloid  blast  crisis.  Thus,  although  BCR-
ABL mutations typify drug resistance in both CML 
and  Ph(+) ALL,  loss  of  INK4-ARF  in  Ph(+) ALL 
enhances disease aggressiveness and attenuates the 
favorable effects of targeted therapy. Super Ink4a/Arf 
mice that have increased copies of the locus manifest 
higher resistance to cancer compared to normal, non-
transgenic mice. Modest increases in the activity of 
the Ink4a/Arf tumor suppressor resulted in a beneficial 
cancer-resistant phenotype without affecting normal 
viability or aging. Thus, the expression of the Ink4a/
Arf tumor suppressor locus is a robust biomarker for 
tumor indolence and resistance.
The  INK4a/ARF  locus  on  chromosome  9p21  is 
frequently  disrupted  in  human  cancers.93  Germline 
mutations of this locus predispose an individual to 
familial  melanomas,  whereas  somatic  mutations 
increase  the  chance  of  sporadic  malignancies  of 
the pancreas and brain. In both mice and humans, 
the  INK4a  locus  includes  two  independent,  but 
overlapping  genes  that  encode  the  gatekeeper 
proteins p16INK4a and p14ARF (p19Arf in mice).94 Each 
gene has its own promoter that precedes three coding 
exons. The first exons for p16INK4a (E1α) and p14ARF 
(E1β) are specific to each gene. Exons 2 and 3 are 
shared,  although  they  are  read  in  different  frames 
and  produce  two  different  proteins.65,95,96  Most 
mutations of the INK4a locus were originally thought 
to  inactivate  p16INK4a.  However,  the  identification 
of ARF, and the finding that ARF and p16INK4a share 
two  exons,  suggests  that  some  mutations  in  the 
INK4a locus may affect only ARF or only p16INK4a, 
whereas others may affect both proteins. The p16INK4a 
protein  is  a  cyclin-dependent  kinase  inhibitor  that 
specifically binds to and inhibits CDK4 and CDK6, 
proteins that promote the G1/S transition.97 Inhibition 
of CDKs leads to maintenance of Rb in its active, 
hypophosphorylated  form  (Fig.  1).  Thus,  p16INK4a 
performs its tumor-suppressor function through the 
functional inactivation of Rb. Rb represses p16INK4a 
expression, and upregulation of p16INK4a expression 
is  observed  in  Rb-deficient  cells.98,99  Expression 
of p16INK4a can also be repressed by the polycomb 
family member Bmi-1,100 and by the helix-loop-helix 
protein Id1.90 p16INK4a expression is enhanced by the 
transcription factors Ets1 and Ets2, two downstream 
targets of Ras-Raf-MEK signaling.101
p19Arf  physically  interacts  with  Mdm2  and 
promotes its rapid degradation (Fig. 1), leading to 
p53 stabilization and activation.19,102–107 p53 control 
Arf  expression  in  return,  since  cells  express  high 
levels of Arf in the absence of functional p53.108 The 
main activators of Arf expression are oncoproteins 
such  as  c-Myc,109  adenovirus  E1A,110  Ras,  E2F-1, 
and v-abl, consistent with a role for Arf in sensing 
hyperproliferative  signals.  Conversely,  Bmi-1,111 
Tbx2,112  Twist,113  Pokemon,114  and  AML1/ETO115 
repress  Arf  expression,  whereas  Dmp1  increases 
it.116,117  Induction  of  Arf  expression  by  E2F-1116,118 
provides  a  functional  link  between  the  p16Ink4a/
cyclin D/Cdk4, 6/Rb and the Arf/Mdm2/p53 tumor 
suppression  pathways.  In  addition  to  p16Ink4a  and 
p19Arf, the Ink4 family of CKIs includes p15Ink4b and 
p18Ink4c. These proteins share ~40% identity, contain 
four tandem ankyrin motifs, and specifically inhibit 
Cdk4 and Cdk6.
Knockout models for Ink4a/Arf
A mouse strain (Ink4a/Arfex2–3) in which both Ink4a 
and  Arf  are  deficient  owing  to  deletion  of  their 
common  exons  2  and  3  has  been  created.119  Mice 
heterozygous  for  the  Ink4a/Arfex2–3  mutation  show 
a moderate increase in fibrosarcomas, lymphomas, 
squamous cell carcinomas, and angiosarcomas. Forty 
percent of these tumors exhibit LOH at the Ink4a 
locus.120 Deletion of exon 1β specific to Arf is also 
seen in some of these tumors, suggesting that in these 
cases it is a deficiency of Arf and not p16Ink4a that 
leads to tumor development in mice. Susceptibility 
to tumorigenesis induced by the carcinogen DMBA 
alone or in combination with ultraviolet B irradiation is 
only slightly increased in Ink4a/Arfex2–3 heterozygous 
mice  compared  to  controls.  Mice  homozygous  for 
the Ink4a/Arfex2–3 mutation are viable, suggesting that 
this locus is not essential for embryonic development 
or  survival.  In  fact,  overexpression  of  the  Ink4a 
locus  can  be  detrimental  to  mouse  development. 
Increased  expression  of  p16Ink4a  and Arf  occurs  in Taneja et al
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Bmi1-deficient mice, which are underdeveloped and 
have a cerebellum and lymphoid organs of reduced 
size. Interestingly, these defects are either completely 
or partially rescued in a homozygous Ink4a/Arfex2–3 
background.111
As  expected,  Ink4a/Arfex2–3-/-  mice  show  an 
increased  susceptibility  to  cancer,  with  most 
developing  sarcomas  and  lymphomas  by  age 
7  months.  Earlier  onset  of  these  malignancies  (at 
about 13 weeks) is observed in Ink4a/Arfex2–3-/- mice 
treated  with  DMBA  or  ultraviolet  B  irradiation. 
Surprisingly, in contrast to humans, mutations of the 
INK4a locus do not predispose mice to melanoma. 
However, Ink4a/Arfex2–3-/- mice that overexpress an 
activated  H-rasG12V  gene  in  melanocytes  develop 
cutaneous  melanomas  with  high  penetrance  by 
age 5.5 months.121 This finding suggests that a loss 
of function of the Ink4a locus coupled with a gain 
of function of ras can result in mice predisposed to 
melanomas.  Although  studies  of  Ink4a/Arfex2–3-/- 
mice indicate that the Ink4a locus is important for 
tumor suppression, the specific roles of p16Ink4a and 
p19Arf cannot be determined in these animals. Mice 
deficient for p19Arf, but competent for p16Ink4a, have 
been  generated  by  deleting  the  Arf-specific  exon 
1β.122–124 Mice heterozygous for this mutation develop 
lymphomas, sarcomas, and hemangiomas after a long 
latency. The tumors show loss of the remaining Arf 
allele and/or lack of its expression, confirming Arf’s 
role in tumor suppression. Homozygous Arf-/- mice are 
viable and fertile, but most develop sarcomas (~40%) 
and T cell lymphomas (~30%) at around 6 months of 
age and often die by 12 months. Interestingly, Arf-/- 
mice  differ  from  Ink4a/Arfex2–3-/-  mice  in  several 
phenotypes. The latency period for tumor formation 
is  shorter  in  untreated  and  DMBA-treated  Ink4a/
Arfex2–3-/-  mice  (~32  and  ~12  weeks,  respectively) 
than in untreated and DMBA-treated Arf-/- mice (~38 
and ~24 weeks, respectively). In addition, Arf-/- mice 
develop carcinomas and tumors of the nervous system 
that do not appear in Ink4a/Arfex2–3-/- mice.123
Two  different  groups  created  knockout  mice 
specific to p16Ink4a by deleting exon 1α or mutating 
exon  2,  respectively.125,126  Krimpenfort  et  al126 
generated mice carrying a point mutation specifically 
affecting  p16Ink4a.  This  allele,  designated  Ink4a*, 
is silent in the p19Arf reading frame, but introduces 
a  stop  codon  in  p16Ink4a  at  conserved  amino-acid 
position  101,  resulting  in  deletion  of  the  fourth 
ankyrin  repeat  motif.  The  analogous  human  allele 
(CDKN2 A-W110X) is a naturally occurring mutation 
found in many human tumor types, and results in an 
unstable protein that poorly inhibits phosphorylation 
of  RB1,  and  thus,  cell-cycle  arrest  in  transfected 
cells.126 These mice, designated Ink4a*/*, did not show 
a  significant  predisposition  to  spontaneous  tumor 
formation within 17 months. Ink4a*/* mouse embryonic 
fibroblasts  proliferated  normally,  were  mortal, 
and  were  not  transformed  by  oncogenic  H-RAS. 
However, Sharpless et al reported that p16Ink4a-null 
mouse embryonic fibroblasts exhibited an increased 
rate of immortalization, although less than observed 
previously for cells null for Ink4a/Arf, Arf, or p53.125 
Moreover, T cells deficient in p16Ink4a exon 1α exhibited 
enhanced mitogenic responsiveness, consistent with 
the established role of p16Ink4a in constraining cellular 
proliferation.  Furthermore,  p16Ink4a  deficiency  was 
associated with an increased incidence of spontaneous 
and carcinogen-induced cancers.125 Ink4a*/∆2,3 mice 
that were deficient for Ink4a and heterozygous for Arf 
spontaneously developed a wide spectrum of tumors, 
including melanoma. Treatment of these mice with the 
carcinogen DMBA resulted in an increased incidence 
of melanoma, with frequent metastasis.126 Thus, the 
results from these two studies indicated that Ink4a 
is  a  tumor-suppressor  gene  that,  when  lost,  could 
recapitulate the tumor predisposition seen in humans.
Expression of Arf in tissues of adult mice is difficult 
to detect, possibly because its induction leads to the 
arrest or elimination of incipient tumor cells. Zindy 
et al replaced exon 1β of the mouse cellular Arf gene 
with a cDNA encoding GFP, thereby producing Arf-
null mice in which GFP expression is driven by the 
endogenous Arf promoter.127 The Arf promoter was 
induced in several biologic settings previously shown 
to elicit mouse p19Arf expression. GFP was expressed in 
cultured mouse embryonic fibroblasts, spontaneously 
arising  tumors,  Eµ-Myc-induced  lymphomas,  and 
retrolental  masses  in  the  vitreous  of  the  eye.  This 
study provided direct evidence that the Arf promoter 
monitors latent oncogenic signals in vivo.
INK4-ARF  genes  are  epigenetically  silenced  in 
hematopoietic  stem  cells,128  but  become  ready  to 
respond to oncogenic stress as blood cells differentiate. 
Thus,  inactivation  of   INK4-ARF  provides  differen-
tiated cells with an inappropriate self-renewal capacity, Transgenic tumor suppressor models
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a  defining  feature  of  cancer  cells.  In  BCR-ABL-
induced (Philadelphia chromosome-positive [Ph(+)]) 
leukemias, INK4-ARF deletions frequently occur in 
clinically aggressive acute lymphoblastic leukemias 
(Ph(+) ALLs), but are not seen in more indolent Ph(+) 
forms  of  chronic  myelogenous  leukemia  (CML) 
or  in  CML  myeloid  blast  crisis.  Williams  et  al129 
infected  mouse  bone  marrow  cells  with  retrovirus 
encoding either of two oncogenic Bcr-Abl isoforms 
[p210(Bcr-Abl)  and  p185(Bcr-Abl)]  and  induced 
B cell lympholeukemias by transplanting the cells into 
lethally irradiated mice. When mouse bone marrow 
cells expressing Bcr-Abl were placed in short-term 
cultures selectively designed to support the outgrowth 
of pre-B cells, only those lacking one or two Arf alleles 
could  initiate  lympholeukemias  when  inoculated 
into immunocompetent recipient mice. Although the 
ABL  kinase  inhibitor  imatinib  mesylate  (Gleevec) 
provides highly effective treatment for BCR-ABL-
positive CML, it has proven far less efficacious in the 
treatment of BCR-ABL-positive acute lymphoblastic 
leukemias (ALL), many of which sustain deletions of 
the INK4A-ARF locus. Consistently, mice receiving 
Arf-/-  or  Arf+/-  p210(Bcr-Abl)-positive  pre-B  cells 
did not achieve remission when maintained on high 
doses of oral imatinib therapy and rapidly developed 
lympholeukemia.129
Although  cells  expressing  the  Bcr-Abl  kinase 
can proliferate in the absence of IL-7, they remain 
responsive to this cytokine, which can reduce their 
sensitivity  to  imatinib.130,131  Treatment  of  Arf-/-, 
p210(Bcr-Abl)-positive  pre-B  cells  with  imatinib 
together with an inhibitor of JAK kinases abrogated 
this resistance, suggesting that this combination may 
prove beneficial in the treatment of  BCR-ABL-positive 
acute lymphoblastic leukemia. Thus, although BCR-
ABL mutations typify drug resistance in both CML and 
Ph(+) ALL, loss of INK4-ARF in Ph(+) ALL enhances 
disease aggressiveness and attenuates the favorable 
effects of targeted therapy. In their following study, 
Williams  et  al132  showed  that  intravenous  infusion 
of  20  Arf-/-,  p185(Bcr-Abl)-positive  pre-B  cells 
into  healthy  syngeneic  mice  induced  rapidly  fatal, 
transplantable  lymphoblastic  leukemias  that  resist 
imatinib therapy. However, introduction of BCR-ABL 
into Arf-null severe combined immunodeficient bone 
marrow  progenitors  lacking  the  cytokine  receptor 
common gamma-chain yielded leukemogenic pre-B 
cells with greater sensitivity to imatinib in vivo. Hence, 
cytokines in the hematopoietic microenvironment can 
facilitate leukemic proliferation and confer resistance 
to targeted therapy.132
Transgenic models for Ink4a/Arf
Yang et al133 created MMTV-p16Ink4a transgenic mice 
and studied the effect of p16Ink4a in ErbB2-induced 
mammary  tumorigenesis.  They  reported  that  the 
p16Ink4a tumor suppressor specifically blocks cyclin-
dependent kinase 4 and 6 activity. The p16Ink4a transgene 
blocked  tumorigenesis  by  ErbB2,  demonstrating 
that  deregulation  of  the  cyclin-dependent  kinase 
partner of cyclin D1 is an essential target of ErbB2. 
ErbB2  overexpression  was  a  determining  factor 
in  deregulation  of  cyclin  D1-Cdk4/6  interactions 
because  neither  transgenic  cyclin  D1  nor  loss  of 
p16Ink4a accelerated tumorigenesis in MMTV-ErbB2-
transgenic mice. ErbB2 was also a deciding factor in 
deregulation of cyclin D1-Cdk4/6 in human tumors 
because no loss of Rb or p16Ink4a was found in tumors 
overexpressing  ErbB2,  although  ErbB2-negative 
invasive  breast  adenocarcinomas  frequently  lacked 
expression of p16Ink4a or pRb.
Mathew et al134 generated a “super Ink4a/Arf” mouse 
strain carrying a transgenic copy of the entire Ink4a/
Arf locus. Cells derived from super Ink4a/Arf mice 
had increased resistance to in vitro immortalization 
and  oncogenic  transformation.  Importantly,  super 
Ink4a/Arf mice manifest higher resistance to cancer 
compared  to  normal,  non-transgenic  mice.  Super 
Ink4a/Arf  mice  had  normal  aging  and  lifespan. 
Thus, modest increases in the activity of the Ink4a/
Arf tumor suppressor resulted in a beneficial cancer-
resistant phenotype without affecting normal viability 
or aging. Matheu et al then crossed “super Ink4a/
Arf” mice with “super p53” mice reasoning that Arf/
p53  could  have  anti-ageing  activity  by  alleviating 
the  load  of  age-associated  damage.135  The  double 
transgenic mice showed strong cancer resistance and 
had decreased levels of ageing-associated damage. 
These observations extend the protective role of Arf/
p53 to ageing, revealing a previously unknown anti-
ageing mechanism and provided a rationale for the 
co-evolution of cancer resistance and longevity.
The  same  group  later  studied  the  impact  of 
increased dosage of the Ink4a/Arf locus on germ 
cells.136 Increased gene dosage of Ink4/Arf impaired Taneja et al
248  Clinical Medicine Insights: Oncology 2011:5
the  production  of  male  germ  cells,  and  in  the 
case  of  Ink4/Arf-tg/tg  mice  results  in  a  Sertoli 
  cell-only-like  syndrome  and  a  complete  absence 
of sperm. There was a lower incidence of aging-
associated cancer proportional to the Ink4/Arf gene 
dosage.   Interestingly, increased Ink4/Arf gene dos-
age resulted in lower scores in aging markers and in 
extended median longevity. The increased survival 
was also observed in cancer-free mice indicating 
that cancer protection and delayed aging are sepa-
rable activities of the Ink4/Arf locus. In contrast, 
mice carrying one or two additional copies of the 
p53 gene (p53-tg and p53-tg/tg) had a normal lon-
gevity despite their increased cancer protection.136 
Thus,  the  Ink4/Arf  locus  has  a  global  anti-aging 
effect,  possibly  by  favoring  quiescence  and  pre-
venting unnecessary proliferation.
The  p16Ink4a  tumor  suppressor  accumulates  in 
many tissues as a function of advancing age. p16Ink4a 
is  an  effector  of  senescence19,66,124,125  and  a  potent 
inhibitor of the proliferative kinase Cdk4, which is 
essential for pancreatic β-cell proliferation in adult 
mammals. To study the links between senescence and 
aging in vivo, Krishnamurthy et al examined Ink4a/
Arf  expression  in  mouse  models  of  aging.137 They 
showed that expression of p16Ink4a and Arf markedly 
increased in almost all mouse tissues with advancing 
age, while there was little change in the expression of 
other Ink4a (p15, p18, and p19) cell cycle inhibitors. 
Importantly, the increase in expression for Ink4a and 
Arf occurred in both epithelial and stromal cells. The 
age-associated increase in expression of p16Ink4a and 
Arf was attenuated in the kidney, ovary, and heart 
by  caloric  restriction,  and  this  decrease  correlated 
with  diminished  expression  of  an  in  vivo  marker 
of  senescence,  as  well  as  decreased  pathology  of 
those  organs.  Thus,  the  expression  of  the  Ink4a/
Arf  tumor  suppressor  locus  is  a  robust  biomarker, 
and  possible  effector  of  mammalian  aging.137  To 
determine the physiological significance of p16Ink4a 
accumulation  on  islet  function,  they  assessed  the 
impact of p16Ink4a-deficiency and overexpression with 
increasing age and in the regenerative response after 
exposure to a specific beta-cell toxin.138 Transgenic 
mice that overexpress p16Ink4a to a degree seen with 
ageing  demonstrated  decreased  islet  proliferation. 
Similarly,  islet  proliferation  was  unaffected  by 
p16Ink4a-deficiency in young mice, but was relatively 
increased  in  p16Ink4a-deficient  old  mice.  Survival 
after  toxin-mediated  ablation  of  beta-cells,  which 
requires islet proliferation, declined with advancing 
age;  however,  mice  lacking  p16Ink4a  demonstrated 
enhanced islet proliferation and survival after beta-
cell ablation. These genetic data support the view that 
an age-induced increase of p16Ink4a expression limits 
the regenerative capacity of beta-cells with ageing.138
p15Ink4b, p18Ink4c, and p19Ink4d models
There  is  no  strong  evidence  that  p15Ink4b,  p18Ink4c, 
and/or  p19Ink4d  are  involved  in  tumor  suppression 
in  humans.  However,  methylation  of  INK4C  is 
observed in human gliomas, and the p18INK4C protein 
is not detectable in 20% of medulloblastoma cases. 
When combined with Ptc1 mutation, Ink4c shows 
haplo-insufficiency  for  tumor  suppression.  Thus, 
p18INK4C  loss  may  contribute  to  medulloblastoma 
formation in children.
In contrast to p16Ink4a, there is no strong evidence 
that p15Ink4b, p18Ink4c, and/or p19Ink4d are involved in 
tumor suppression in humans. Although the p15INK4b 
locus is often deleted in human tumors, its deletion 
is concomitant with that of the neighboring INK4a/
ARF  locus.  Gene-targeted  mice  hemizygous  for 
p18Ink4c or p15Ink4b did not show increased incidence 
of  cancer.139,140  Like  other  Ink4  family  members, 
p18Ink4c and p15Ink4b are not required for embryonic 
development. Ablation of these genes, either alone 
or  in  combination,  did  not  abrogate  cell  contact 
inhibition or senescence of mouse embryo fibroblasts 
in culture. However, loss of p15Ink4b, but not p18Ink4c, 
conferred proliferative advantage to these cells and 
made them more sensitive to transformation by H-Ras 
oncogenes.140  p18Ink4c-/-  mice  developed  pituitary 
adenomas  (40%,  mostly  chromophobe  adenomas), 
testicular tumors (12%), and adrenal tumors (10%) 
that lead to death before 18 months of age. In contrast, 
the cancer susceptibility of p15Ink4b-/- mice was only 
slightly increased over controls; angiosarcomas were 
observed in fewer than 10% of older p15Ink4b-/- mice.140 
Ablation of both p15Ink4b and p18Ink4c genes resulted in 
lymphoproliferative disorders and tumor formation. 
Moreover, mice lacking p18Ink4c exhibited deregulated 
epithelial  cell  growth  leading  to  the  formation  of 
cysts, mostly in the cortical region of the kidneys and 
the mammary epithelium. These results indicate that 
p15Ink4b and p18Ink4c are tumor suppressor proteins that Transgenic tumor suppressor models
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act in different cellular lineages and/or pathways with 
limited compensatory roles. Mice with nullizygous or 
heterozygous mutations of p27Kip1 were predisposed 
to tumors in multiple tissues when challenged with 
γ-irradiation  or  a  chemical  carcinogen.141  Mice 
lacking both p18Ink4c and p27Kip1, like chimeric mice 
for Rb deficiency, developed pituitary tumors and died 
by 3.5 months of age.139 Hence, p18Ink4c and p27Kip1 
mediate  two  separate  pathways  to  collaboratively 
suppress pituitary tumorigenesis, likely by controlling 
the function of Rb.
Overlapping and sustained patterns of expression 
of two cyclin-dependent kinases, p19Ink4d and p27Kip1, 
in post-mitotic brain cells suggested that these pro-
teins may be important in actively repressing neuronal 
proliferation. Animals derived from crosses of Ink4d- 
null with kip1-null mice exhibited bradykinesia, pro-
prioceptive abnormalities, and seizures, and died as 
early  as  18  days  after  birth.142  Metabolic  labeling 
of live animals with neuronal markers showed that 
subpopulations  of  central  nervous  system  neurons 
were proliferating in all parts of the brain, including 
normally dormant cells of the hippocampus, cortex, 
hypothalamus, pons, and brain stem.142 These cells 
also  expressed  G2/M  marker  phosphorylated  his-
tone H3, indicating that neurons were dividing after 
they had migrated to their final positions in the brain. 
Increased proliferation was balanced by cell death, 
resulting  in  no  gross  changes  in  the  cytoarchitec-
ture of the brains of these mice. Therefore, the Cdk 
inhibitors p19Ink4d and p27Kip1 cooperate to maintain 
differentiated  neurons  in  a  quiescent  state  that  is 
potentially  reversible.  Thus,  inhibiting  function  of 
these Cdk inhibitors in the adult brain could provide 
an  avenue  for  stimulating  the  growth  of  neuronal 
populations lost in degenerative diseases or through 
traumatic injury.142
Recurrent genetic alterations in human medullo-
blastoma  include  mutations  in  the  sonic  hedgehog 
  signaling pathway and TP53 inactivation (approxi-
mately 25% and 10% of cases, respectively).   However, 
mouse models of medulloblastoma generally depend 
upon  p53  inactivation  for  rapid  onset  and  high 
  penetrance. The p18Ink4c gene is transiently expressed 
in  mouse  cerebellar  granule  neuronal  precursor 
cells (GNPs) as they exit the cell division cycle and 
  differentiate. Co-inactivation of Ink4c and p53 pro-
vided cultured GNPs with an additive proliferative 
advantage, either in the presence or absence of Shh, 
and induced medulloblastoma with low penetrance, 
but with greatly increased the incidence following 
postnatal  irradiation.143  In  contrast,  mice  lacking 
one or two functional Ink4c alleles and one copy of 
Patched  (Ptc1)  encoding  the  Shh    receptor  rapidly 
developed medulloblastomas that retained wild-type 
p53.143 In tumor cells purified from double heterozy-
gotes, the wild-type Ptc1 allele, but not Ink4c, was 
  inactivated.  Therefore,  when  combined  with  Ptc1 
mutation,  Ink4c  is  haploinsufficient  for  tumor 
suppression.   Methylation of INK4C was observed in 
four of 23 human medulloblastomas, and the p18INK4C 
protein was not detectable in 14 of 73 cases. Hence, 
p18INK4C  loss  may  contribute  to  medulloblastoma 
  formation in children.142
BRCA models
A substantial part of hereditary breast cancer cases 
is  caused  by  BRCA1  germline  mutations.  Trans-
genic BRCA1 mice showed delayed development 
of tumors when challenged with DMBA, relative 
control  mice.  Mouse  models  with  conventional 
and  conditional  mutations  in  Brca1/2  have  dem-
onstrated critical roles of these proteins in breast 
cacinogenesis. The most advanced mouse models 
closely  reproduce  human  BRCA1/2-related  breast 
cancers, and may, therefore be useful for addressing 
clinically relevant questions including novel drug 
screens.
BRCA1
In  humans,  inheritance  of  one  mutated  allele  of 
BRCA1 significantly increases the risk of breast or 
ovarian cancer.144–146 Mutations of the BRCA1 gene, 
located on chromosome 17q21, are a predisposing 
factor  in  approximately  50%  of  families  with 
hereditary breast cancer and in over 80% of families 
with hereditary breast-ovarian cancer. Most tumors 
from predisposed individuals demonstrate LOH for 
the wild-type BRCA1 allele, and thus it is a classical 
tumor suppressor. BRCA1 expression is increased in 
the S phase of the cell cycle, and the BRCA1 protein 
is phosphorylated in a cell cycle-dependent manner 
and in response to DNA damage.146
Several  lines  of  evidence  support  a  role  for 
BRCA1  in  DNA  damage  repair.  BRCA1  is  phos-
phorylated  following  activation  of  ATM,  CHK2, Taneja et al
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and  ATR-dependent  DNA  damage  signaling  path-
ways.  Furthermore,  BRCA1  interacts  or  forms  a 
complex  with  multiple  proteins  involved  in  DNA 
damage  repair,  including  RAD51,  RAD50-Mre11-
p95, MSH2, MSH6, MLH1, ATM, CHK2, BRCA2, 
and  BLM.147  BRCA1  also  interacts  with  proteins 
that are involved in transcription, such as the RNA 
polymerase  II  holoenzyme  complex,  RNA  heli-
case A, CtIP (CTBP-interacting protein), and CBP/
p300. Unlike humans with an inherited BRCA1 muta-
tion, however, mice hemizygous for a Brca1 muta-
tion  do  not  show  increased  incidence  of  tumors. 
Homozygous  Brca1  mutations  inevitably  lead  to 
post-implantation  embryonic  lethality.148–151  How-
ever,  phenotypic  differences  exist  among  different 
Brca1-/- strains, such as a range of the onset of lethal-
ity from E6.5 to E13.152 Such differences could be due 
to different types of targeted Brca1 mutations and/or 
to the frequent alternative splicing of this gene during 
embryogenesis.
Brca1-/-  embryos  exhibit  defective  cellular  pro-
liferation  and  activation  of  p53-dependent  path-
ways.153 Mutation of p53 or its transcription target 
p21Cip1 partially delays the lethality of the Brca1-/- 
embryos.151,153,154 Hypomorphic Brca1 mutants with 
a  partial  loss  of  Brca1  function  show  spina  bifida 
and  anencephaly  accompanied  by  increased  apop-
tosis in the neuroepithelium and die at E10-E13.148 
Hypomorphic  Brca1-mutant  ES  cells  and  MEFs 
are hypersensitive to IR155,156 and have a defect in 
transcription-coupled  DNA  repair.  Human  BRCA1 
transgenes  can  rescue  the  embryonic  lethality  of 
Brca1 mutant mice.157,158
Three different conditional Brca1 alleles have been 
generated, Brca1F5–6, Brca1Co, and Brca1F5–13.159–161 
Cre-mediated  deletion  of  Brca1  exons  5–6  or 
exons  5–13  from  the  Brca1F5–6  or  Brca1F5–13 allele, 
respectively,  induces  a  frameshift  mutation  that 
abrogates the production of all three splicing products 
(full-length Brca1, Brca1-D11, and Brca1-IRIS). In 
contrast,  deletion  of  exon  11  of  the  Brca1Co  allele 
results in a hypomorphic mutation that still allows 
for expression of Brca1-D11. Mice with a mammary 
gland-specific hypomorphic Brca1 function showed 
increased mammary cell apoptosis and abnormal ductal 
development, including incomplete ductal outgrowth, 
alveolar differentiation and involution, suggesting that 
Brca1 function is indispensable for normal mammary 
gland  development.160  These  mice  developed 
mammary  gland  tumors  after  10  to  13  months  of 
age that showed genetic instability characterized by 
aneuploidy  and  chromosomal  rearrangements,  or 
alteration of p53 transcription. This model was later 
improved by introduction of a single p53-null allele, 
yielding MMTV-Cre; Brca1Co/Co; p53+/- mice, which 
developed mammary tumors with reduced latency.162 
Cooperation between Brca1 and p53 loss in mammary 
tumorigenesis was also demonstrated in a K14-Cre; 
Brca1F5–13/F5–13; p53F2–10/F2–10 mouse model with tissue-
specific inactivation of both Brca1 and p53.161 The fact 
that loss of p53 function accelerates the formation of 
mammary tumors in female mice with the mammary 
gland-specific Brca1 mutation paralleled the frequent 
loss of TP53 in tumors from human BRCA1 patients. 
Mice with a T cell lineage–specific null mutation of 
Brca1 exhibit depletion of T lineage cells, abnormal 
p53 activation, and decreased cell cycle progression, 
and apoptosis.159
To directly determine the role of BRCA1 in mam-
mary gland development and tumor suppression, a 
transgenic mouse model of BRCA1 overexpression was 
developed.163  Using  the  MMTV  promoter/enhancer, 
transgenic mice expressing human BRCA1 or select 
mutant controls were generated. Transgenic animals 
examined during adolescence expressed the human 
transgene in their mammary glands. The mammary 
glands of 13-week-old virgin homozygous MMTV-
BRCA1 mice showed moderately increased lobulo-
alveolar development. The mammary ductal trees of 
both hemizygous and homozygous MMTV-BRCA1t340 
were  similar  to  those  of  control  non-transgenic 
  littermates.  Interestingly,  both  hemi-  and  homozy-
gous transgenic mice expressing a splice variant of 
BRCA1 lacking the N-terminal RING finger domain 
(MMTV-BRCA1sv) and exhibited marked mammary 
lobulo-alveolar  development,  particularly  terminal 
end bud proliferation. Homozygous MMTV-BRCA1 
mice showed delayed development of tumors when 
challenged with DMBA, relative to non-  transgenic 
and homozygous BRCA1t340 expressing mice. In con-
trast,  homozygous  MMTV-BRCA1sv  transgenic  ani-
mals were sensitized to DMBA treatment exhibited 
a very rapid onset of mammary tumor development 
and accelerated mortality. MMTV-BRCA1 effects on 
mortality were restricted to DMBA-induced tumors of 
the mammary gland. These results demonstrate in vivo Transgenic tumor suppressor models
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roles for BRCA1 in both mammary gland development 
and in tumor suppression against   mutagen-induced 
mammary gland neoplasia.163
BRCA2
The human BRCA2 gene is located on chromosome 
13q12-q13, and encodes a major transcript of 11 kb 
that is translated into a highly charged 3,418 amino 
acid  protein.146,153  In  women,  mutations  of  BRCA2 
are responsible for 32% of hereditary breast cancers. 
BRCA2 mutations are also related to increased breast 
cancer in men. Like BRCA1, BRCA2 is thought to 
act as a caretaker involved in DNA damage repair and 
the maintenance of genomic integrity. BRCA1 and 
BRCA2 co-immunoprecipitate and co-localize with 
RAD51 in subnuclear foci and on the axial elements 
of developing synaptonemal complexes. Furthermore, 
BRCA2,  like  BRCA1  and  RAD51,  relocates  to 
PCNA-positive replication sites following exposure 
of S phase cells to HU or ultraviolet irradiation.142
Brca2-/-  mice  die  in  utero  between  E7.5  and 
E9.5.164–166 The onset of abnormalities is seen as early 
as E5.5 and the mutant embryos remain underdevel-
oped until death. Defective cell proliferation occurs in 
vivo and in vitro. Some hypomorphic Brca2 mutants 
survive to adulthood.167–169 These animals are smaller 
than  their  control  littermates,  show  abnormal  tis-
sue   differentiation, lack germ cells, and are infertile. 
Brca2 hypomorphs develop lethal thymic lymphomas 
by 12–14 weeks of age. Mammary gland tumors were 
not  observed,  possibly  because  these  animals  died 
early. It is unclear whether Brca2 mutations in mice 
will accurately reproduce human pathologies. Brca2-
deficient cells have defects in their ability to repair 
DNA  damage  induced  by  genotoxic  agents  such 
as γ-, X-ray, and ultraviolet irradiation, and MEFs 
of  Brca2  hypomorphic  mutants  exhibit  genomic 
instability.146,147,169–171
To achieve mammary gland-specific recombina-
tion of a Brca2F3–4 conditional allele, Ludwig et al172 
created knock-in mice for Brca2F3–4 and crossed with 
WAP-Cre. Wapcre/+; Brca2ex11/F3–4 female mice devel-
oped  non-metastatic mammary carcinomas or  ade-
nosquamous carcinomas after a relatively long latency 
of 1.4 years.172 The tumors displayed aneuploidy and 
chromosomal aberrations, were ErbB2/neu-negative, 
and ERα and cyclin D1-positive. Cheung et al173 cre-
ated  conditional  Brca2F9–10  mice  and  crossed  them 
with MMTV- or WAP-Cre transgenic lines. Although 
Brca2 was not required for epithelial expansion in 
mammary glands of pregnant mice, Brca2-deficient 
mice  developed  mammary  adenocarcinomas  after 
a long latency (average: 1.6 years). Detailed histo-
pathological analysis of four of these tumors dem-
onstrated that three of them showed abnormal p53 
protein  expression.  Moreover,  homozygosity  ver-
sus  heterozygosity  for  the  Brca2  mutation  heavily 
skewed the tumor spectrum toward mammary ade-
nocarcinoma  development  in  p53+/−  mice.  Thus, 
although Brca2 is not essential for mammary epi-
thelial development, Brca2-deficiency and hemizy-
gous p53 deletion collaborate to promote mammary 
tumorigenesis.
Brca2  is  also  implicated  in  T  cell  lymphoma 
development. A small acceleration of T cell lympho-
magenesis was reported for Lck-Cre; Brca2F9–10/F9–10; 
p53-/-  mice,  compared  to  Lck-Cre;  p53-/-  control 
animals.174  However,  Park  and  Lee175  found  that 
thymus-specific disruption of  Brca2F12/F12 allele in mice 
that were not crossed to a p53-mutant background also 
led to development of thymic lymphomas. The tumors 
were fatal in 25% of these mice from 16 weeks to 66 
weeks  after  birth.  The  difference  between  the  two 
studies could be due to different targeting sites between 
the two types of mice or different genetic backgrounds 
(129/C57BL/6 vs. FVB). Park and Lee1175 had targeted 
exon 11 of Brca2, whereas Cheung and colleagues 
had targeted exon 9 and 10 of Brca2 allele.174 The 
very  large  exon  11  of  Brca2  contains  6–8  BRC 
repeats, which are implicated in Rad51-binding and 
modulating DNA repair. Therefore, it was speculated 
that targeting exon 11 of Brca2 would yield better 
survival and less genetic instability. Nevertheless, the 
results from Park and Lee indicate that Brca2 mutation 
in T cells predisposed them to mutations that led to 
cancer.
BRCA2 has also been implicated in the etiology 
of prostate cancer, but the impact of Brca2 mutations 
in prostate tumorigenesis is unclear. Francis et al177 
showed  that  deletion  of  Brca2  specifically  in 
prostate  epithelia  results  in  focal  hyperplasia  and 
low-grade  prostate  intraepithelial  neoplasia  (PIN) 
in  animals  over  12  months  of  age.  Simultaneous 
deletion  of  Brca2  and  p53  in  prostate  epithelia 
gave rise to focal hyperplasia and atypical cells at 
6  months,  leading  to  high-grade  PIN  in  animals Taneja et al
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from 12 months.176–177 Epithelial cells in these lesions 
showed  increased  DNA  damage  and  had  higher 
levels of proliferation, but also elevated apoptosis. 
Castration  of  Brca2;  p53  mutant  animals  led  to 
regression of PIN lesions, but atypical cells continued 
to proliferate and express nuclear androgen receptor. 
This study provided evidence that Brca2 can act as a 
tumor suppressor in the prostate, which could guide 
the development of new therapeutic approaches to 
prostate cancer.177
Novel tumor suppressor ARH1
ARHI  is  an  imprinted  TSG  in  breast  and  ovarian 
carcinomas;  expression  of  ARHI  in  cancer  cells 
inhibits  cell  growth  and  is  associated  with  down-
regulation  of  the  Cyclin  D1  promoter  activity  and 
induction of p21WAF1/CIP1. Identification of these novel 
Ras-related GTPase family members has expanded 
our understanding of the roles of these proteins in 
cell physiology. ARH1 serves as functionally distinct 
regulators  of  as  yet  to  be  characterized  signaling 
cascades.
Using differential display PCR, Yu et al identified 
a gene ARH1 (A Ras homologue member 1; NOEY2) 
with high homology to ras and rap that is expressed 
consistently  in  normal  ovarian  and  breast  epithe-
lial cells, but not in ovarian and breast cancers.178 
  Re-expression of ARH1 by transfection suppresses 
clonogenic growth of breast and ovarian cancer cells. 
Growth suppression by ARH1 was associated with 
down-regulation  of  the  Cyclin  D1  promoter  activ-
ity and induction of p21WAF1/CIP1. LOH of ARH1 was 
detected in 41% of ovarian and breast cancers. In 
most cancer samples with LOH, the non-imprinted 
functional ARH1 allele was deleted, indicating that 
ARH1 is a classical tumor suppressor.
Xu et al179 developed transgenic mice that overex-
press ARH1 under the control of the CMV promoter. 
Offspring with the transgene weighed significantly 
less  than  non-transgenic  littermates.  In  addition, 
strong expression of the ARH1 transgene was associ-
ated with greatly impaired mammary gland develop-
ment and lactation, failure of ovarian folliculogenesis 
resulting in decreased fertility, loss of neurons in the 
cerebellar cortex, and impaired development of the 
thymus.  Decrease  in  body  size  and  defects  in  the 
mammary glands correlated with the level of trans-
gene  expression.  Immunohistochemical  analysis 
indicated that expression of prolactin (but not growth 
hormone) was lower in the pituitary glands of mice 
with  defective  mammary  gland  development.  The 
defect  in  pregnancy-associated  mammary  tissue 
proliferation was associated with decreased serum 
prolactin and progesterone levels. Moreover, lower 
levels of estrogen receptor and progesterone recep-
tor were observed in postpartum mammary glands 
and in the ovaries of mice that overexpressed ARH1. 
Thus,  ARH1  can  inhibit  prolactin  secretion  and 
act  as  a  negative  regulator  in  murine  growth  and 
development.179
ARH1 is downregulated in more than 60% of human 
ovarian cancers. Lu et al180 showed that re-expression 
of ARH1 in multiple ovarian cancer cell lines induced 
autophagy by blocking PI3 K signaling and inhibiting 
mammalian target of rapamycin mTOR, upregulating 
ATG4, and colocalizing with cleaved microtubule-
associated protein light chain 3 in autophagosomes. 
Furthermore,  ARH1  was  required  for  spontaneous 
and  rapamycin-induced  autophagy  in  normal  and 
malignant  cells. Although  ARH1  re-expression  led 
to  autophagic  cell  death  when  SKOV3  ovarian 
cancer  cells  were  grown  in  culture,  it  enabled  the 
cells  to  remain  dormant  when  they  were  grown 
in  mice  as  xenografts.  When  ARH1  levels  were 
reduced in dormant cells, xenografts grew rapidly. 
However,  inhibition  of  ARH1-induced  autophagy 
with chloroquine dramatically reduced re-growth of 
xenografted tumors upon reduction of ARH1 levels, 
suggesting that autophagy contributed to the survival 
of dormant cells.
ARH1 is also frequently lost in pancreatic cancers. 
ARH1  was  re-expressed  in  pancreatic  cancer  cells 
that had lost its expression to demonstrate the molec-
ular mechanisms of cell growth inhibition.180 Flow 
cytometric  analysis  indicated  that  ARH1  blocked 
cell cycle progression at the G1 phase in pancreatic 
cancer cells. Re-expression of ARH1 increased the 
expression of p21WAF1, through the accumulation of 
p53 protein by the inhibition of PI3K/AKT signaling. 
In  addition, ARH1  enhanced  expression  of  p27KIP1 
through the inhibition of PI-3K/AKT signaling. The 
expression of cyclins A and D1 decreased, followed 
by  decreased  activities  of  CDK2/4.  These  results 
suggest that the PI-3K/AKT pathway plays a pivotal 
role  in  the  pathogenesis  of  pancreatic  cancer  and 
ARH1  exerts  its  growth-inhibitory  effects  through Transgenic tumor suppressor models
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modulation  of  several  key  G1  regulatory  proteins, 
such as p21WAF1, p27KIP1, CDK2/4, Cyclins A and D1.
conclusions
Mouse models for TSGs, particularly models gener-
ated by gene targeting, offer the advantage of studying 
a genetically modified animal bearing one or only a 
few mutations. The use of these animals has revealed 
previously unsuspected developmental roles for TSGs 
such as Rb, Brca1, and Brca2, and has advanced our 
overall understanding of tumor-suppressor functions. 
Mouse models for TSGs have greatly facilitated the 
identification and  characterization of  cellular path-
ways controlled by these genes. This knowledge will 
be invaluable in choosing pathways or molecules to 
target for therapy of a specific cancer.
Most mouse models that manipulate TSGs exhibit 
some degree of predisposition to cancer development. 
A closer relationship between the murine and human 
situations  may  be  precluded  by  several  factors. 
Tumorigenesis associated with homozygous, but not 
heterozygous,  mutation  of  a  mouse  TSG  strongly 
suggests that LOH and inactivation of a wild-type 
allele  are  rare  and  limiting  events.  In  addition, 
the  mouse  lifespan  may  be  too  short  to  allow  the 
inactivation of the wild-type allele followed by the 
accumulation of other genetic abnormalities necessary 
for tumor development. For example, the frequent 
thymic lymphomas in the mouse model created by 
Cheung et al174 and Park and Lee175 might preclude 
these animals from developing other tumors owing to 
their early death from lymphomas. Finally, different 
genetic  backgrounds  give  rise  to  different  cancer 
spectra.  Thus,  it  is  not  surprising  that  phenotypic 
differences exist between human diseases and their 
mouse models.
Nevertheless,  the  engineering  of  mouse  models 
with combinations of mutated TSGs and mice trans-
genic for different oncogenes will provide powerful 
systems  for  identifying  synergistic  effects  of  spe-
cific mutations/deletions on tumorigenesis. Where the 
embryonic lethality of a mutation hampers the study 
of gene function in vivo, conditional mutants can be 
generated in which deletion or mutation of a TSG can 
be induced in a tissue of choice. In the future, mouse 
models in which mutation of both alleles of a TSG is 
induced in a few somatic cells will replicate sporadic 
human cancers. The sequencing of the human genome 
will no doubt lead to the identification of still more 
TSGs and oncogenes, and thus even more sophisti-
cated mouse models. The study of such models should 
ultimately be of great benefit to cancer patients.
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